Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.435
+0.025 (0.57%)
Mar 5, 2026, 11:18 AM EST - Market open
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 5.70, with a low estimate of 3.00 and a high estimate of 7.50. The average target predicts an increase of 28.52% from the current stock price of 4.44.
Analyst Consensus: Hold
* Price targets were last updated on Jan 8, 2026.
Analyst Ratings
The average analyst rating for Cytek Biosciences stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +12.74% | Jan 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $7.5 | Buy | Maintains | $8 → $7.5 | +69.11% | Nov 11, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +57.84% | May 28, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $3.5 → $3 | Strong Sell | Maintains | $3.5 → $3 | -32.36% | May 12, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +35.29% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
211.60M
from 201.49M
Increased by 5.02%
Revenue Next Year
228.29M
from 211.60M
Increased by 7.89%
EPS This Year
-0.25
from -0.52
EPS Next Year
-0.20
from -0.25
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 219.7M | 240.1M | |
| Avg | 211.6M | 228.3M | |
| Low | 200.9M | 210.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.0% | 13.4% | |
| Avg | 5.0% | 7.9% | |
| Low | -0.3% | -0.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.24 | -0.18 | |
| Avg | -0.25 | -0.20 | |
| Low | -0.26 | -0.22 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.